Breaking News Instant updates and real-time market news.

VTGN

VistaGen Therapeutics

$0.34

-0.7449 (-68.65%)

10:45
11/14/19
11/14
10:45
11/14/19
10:45

William Blair downgrades VistaGen to Market Perform after MDD trial miss

As previously reported, William Blair analyst Tim Lugo downgraded VistaGen Therapeutics to Market Perform from Outperform after the company announced that the Phase 2 ELEVATE study of AV-101 for the adjunctive treatment of major depressive disorder, or MDD, failed to meet its primary endpoint. The failure of ELEVATE is a setback, but he still views PH94B and PH10 as "intriguing assets," Lugo tells investors. Though he thinks both of those programs hold value, Lugo is concerned with the company's cash position, with $4M on hand as of the last quarter, and its ability to execute on the opportunities he sees for PH94B and PH10, the analyst added. In morning trading, VistaGen is down 72c, or 68%, to 35c per share.

VTGN VistaGen Therapeutics
$0.34

-0.7449 (-68.65%)

07/22/19
CHDN
07/22/19
DOWNGRADE
CHDN
Neutral
VistaGen Therapeutics downgraded to Neutral from Buy at Chardan
08/28/19
WBLR
08/28/19
INITIATION
WBLR
Outperform
VistaGen Therapeutics initiated with an Outperform at William Blair
William Blair started VistaGen Therapeutics with an Outperform rating saying the company's central nervous system pipeline is underappreciated.
08/28/19
WBLR
08/28/19
INITIATION
WBLR
Outperform
VistaGen soars 25% after William Blair initiates with $7 fair value estimate
William Blair analyst Tim Lugo initiated coverage of VistaGen Therapeutics with an Outperform and fair value estimate of $7. The stock in premarket trading is up 25%, or 16c, to 80c. VistaGen is a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for major depressive disorder and social anxiety disorder, Lugo tells investors in a research note. He believes the company "remains an overlooked, undervalued name with differentiated assets in large mood disorder markets." At current valuation levels, VistaGen shares offer an "asymmetric" risk/reward profile, says Lugo. He points out the company's lead asset AV-101 will read out a proof-of-concept study with the placebo-controlled Phase II Elevate trial before year-end 2019. AV-101 is an oral prodrug of 7-Cl-KYNA and has a "strong rationale" to show efficacy in major depressive disorder patients, contends Lugo.
11/14/19
WBLR
11/14/19
DOWNGRADE
WBLR
Market Perform
VistaGen Therapeutics downgraded to Market Perform from Outperform at William Blair
William Blair analyst Tim Lugo downgraded VistaGen Therapeutics to Market Perform from Outperform.

TODAY'S FREE FLY STORIES

AUPH

Aurinia Pharmaceuticals

$15.83

7.45 (88.90%)

11:49
12/05/19
12/05
11:49
12/05/19
11:49
Recommendations
Aurinia Pharmaceuticals analyst commentary  »

Aurinia price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

KMI

Kinder Morgan

$19.45

0.15 (0.78%)

11:45
12/05/19
12/05
11:45
12/05/19
11:45
Options
Kinder Morgan call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNSS

Sunesis

$0.24

-0.1499 (-38.45%)

11:44
12/05/19
12/05
11:44
12/05/19
11:44
Hot Stocks
Sunesis announces data from ongoing Phase 1b/2 trial of vecabrutinib »

Sunesis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

BIIB

Biogen

$286.74

-2.61 (-0.90%)

11:39
12/05/19
12/05
11:39
12/05/19
11:39
Hot Stocks
Biogen down 3% as trading resumes, medical conference presentation continues »

Biogen representatives…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

SAGE

Sage Therapeutics

$63.85

-85.37 (-57.21%)

11:38
12/05/19
12/05
11:38
12/05/19
11:38
Recommendations
Sage Therapeutics analyst commentary  »

Sage Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VST

Vistra Energy

$24.45

-0.66 (-2.63%)

11:35
12/05/19
12/05
11:35
12/05/19
11:35
Options
Vistra Energy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:35
12/05/19
12/05
11:35
12/05/19
11:35
General news
Today's U.S. reports »

Today's U.S. reports…

BIIB

Biogen

$286.74

-2.61 (-0.90%)

11:35
12/05/19
12/05
11:35
12/05/19
11:35
Hot Stocks
Breaking Hot Stocks news story on Biogen 

Biogen trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

11:30
12/05/19
12/05
11:30
12/05/19
11:30
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

ACAD

Acadia

$51.31

7.09 (16.03%)

11:25
12/05/19
12/05
11:25
12/05/19
11:25
Recommendations
Acadia analyst commentary  »

Acadia's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBT

Global Blood Therapeutics

$75.73

1.43 (1.92%)

11:25
12/05/19
12/05
11:25
12/05/19
11:25
Options
Global Blood Therapeutics call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 08

    Dec

  • 26

    Feb

SRC

Spirit Realty

$52.25

-0.82 (-1.55%)

11:25
12/05/19
12/05
11:25
12/05/19
11:25
Conference/Events
Spirit Realty to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

QUIK

QuickLogic

$0.25

(0.00%)

11:22
12/05/19
12/05
11:22
12/05/19
11:22
Hot Stocks
QuickLogic announces death of Chairman E. Thomas Hart »

QuickLogic earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

SPXC

SPX Corporation

$48.37

0.245 (0.51%)

11:19
12/05/19
12/05
11:19
12/05/19
11:19
Conference/Events
SPX Corporation management to meet with Sidoti »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

SAGE

Sage Therapeutics

$65.72

-83.5 (-55.96%)

11:19
12/05/19
12/05
11:19
12/05/19
11:19
Recommendations
Sage Therapeutics analyst commentary  »

Stifel cuts Sage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SXT

Sensient

$63.45

0.24 (0.38%)

11:17
12/05/19
12/05
11:17
12/05/19
11:17
Conference/Events
Sensient management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

BIIB

Biogen

$286.74

-2.61 (-0.90%)

11:17
12/05/19
12/05
11:17
12/05/19
11:17
Hot Stocks
Biogen finalizing details of a re-dosing study for aducanumab »

In slides for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
12/05/19
12/05
11:17
12/05/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAVN

Raven

$34.96

-0.01 (-0.03%)

11:16
12/05/19
12/05
11:16
12/05/19
11:16
Conference/Events
Raven management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
12/05/19
12/05
11:16
12/05/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APEI

American Public Education

$24.77

-0.32 (-1.28%)

11:15
12/05/19
12/05
11:15
12/05/19
11:15
Conference/Events
American Public Education management to meet with Sidoti »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

11:15
12/05/19
12/05
11:15
12/05/19
11:15
General news
Treasury announced $78 B in 3-, 10-, and 30-year maturities »

Treasury announced $78 B…

11:15
12/05/19
12/05
11:15
12/05/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

11:15
12/05/19
12/05
11:15
12/05/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

11:15
12/05/19
12/05
11:15
12/05/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.